Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Blessing C OgbooDepartment of Chemistry, College of Arts and Sciences, The State University of New York at Buffalo, Buffalo, New York 14260, United States.
Kishan B PatelDepartment of Chemistry, College of Arts and Sciences, The State University of New York at Buffalo, Buffalo, New York 14260, United States.
Marta MassariDepartment of Biology and Biotechnology, University of Pavia, Pavia 27100, Italy.ORCID 0000-0002-7731-7626
Sara MarcheseDepartment of Biology and Biotechnology, University of Pavia, Pavia 27100, Italy.ORCID 0000-0002-9722-2616
Joana ReisDepartment of Biology and Biotechnology, University of Pavia, Pavia 27100, Italy.
Emily J JoyceDepartment of Pathology and Laboratory Medicine, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, Vermont 05405, United States.
Miao-Chong J LinDepartment of Pathology and Laboratory Medicine, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, Vermont 05405, United States.
Johnathan D RabbDepartment of Chemistry, College of Arts and Sciences, The State University of New York at Buffalo, Buffalo, New York 14260, United States.ORCID 0000-0002-4248-8740
Omobolanle A AbidakunDepartment of Chemistry, College of Arts and Sciences, The State University of New York at Buffalo, Buffalo, New York 14260, United States.ORCID 0000-0002-2009-947X
Qing LinDepartment of Chemistry, College of Arts and Sciences, The State University of New York at Buffalo, Buffalo, New York 14260, United States.ORCID 0000-0002-9196-5718
Albert van der VlietDepartment of Pathology and Laboratory Medicine, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, Vermont 05405, United States.
Andrea MatteviDepartment of Biology and Biotechnology, University of Pavia, Pavia 27100, Italy.ORCID 0000-0002-9523-7128
David E HeppnerDepartment of Chemistry, College of Arts and Sciences, The State University of New York at Buffalo, Buffalo, New York 14260, United States.ORCID 0000-0002-0722-5160
Funding
University of Buffalo Clinical and Translational Science Institute - Supplement SchulyerUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2015 to 2024
$33.8M
Dual Oxidase in Airway Epithelial Repair and RemodelingR01HL085646 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI VAN DER VLIET, ALBERT · 2008 to 2020
$4.7M
Development and Applications of Bioorthogonal Chemistry: Equipment SupplementR35GM130307 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Qing Lin · 2019 to 2026
$3.6M
Improving Drug Development Through Studies of Protein Kinase InhibitorsR35GM155353 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI David E. Heppner · 2024 to 2026
$1.2M
DUOX1 in fibroblast-macrophage cross-talk in pulmonary fibrosisR21AG075491 · NIA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI VAN DER VLIET, ALBERT · 2022 to 2023
Dysregulated reactive oxygen species (ROS) are implicated in various diseases, positioning NADPH oxidase enzymes (NOXs) as attractive therapeutic targets. However, progress in tool compound discovery has been hindered by rational optimization strategies that can improve isoform selectivity. Starting from a nonselective but well-behaved NOX inhibitor (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Enhancing Selectivity and Potency of S · full record | OpenQuestion